GLP-1 weight loss drugs: Renowned cardiovascular surgeon Dr. Naresh Trehan has issued a stern warning against the unsupervised use of GLP-1 (Glucagon-like peptide-1) drugs, which have flooded the Indian market following recent patent expirations.
Key takeaways
Quick scan — what you need to know:
- GLP-1 weight loss drugs: Renowned cardiovascular surgeon Dr.
- Naresh Trehan has issued a stern warning against the unsupervised use of GLP-1 (Glucagon-like peptide-1) drugs, which have flooded the Indian market following recent patent expirations.
- While originally developed in the U.S.
- for severe obesity and Type 2 diabetes, the entry of low-cost generic versions has led to widespread misuse via online pharmacies and wellness clinics.
Background
What led here, in plain terms:
- GLP-1 weight loss drugs: Renowned cardiovascular surgeon Dr.
- Naresh Trehan has issued a stern warning against the unsupervised use of GLP-1 (Glucagon-like peptide-1) drugs, which have flooded the Indian market following recent patent expirations.
- While originally developed in the U.S.
- for severe obesity and Type 2 diabetes, the entry of low-cost generic versions has led to widespread misuse via online pharmacies and wellness clinics.
Why it matters
Why readers and decision-makers should care:
- GLP-1 weight loss drugs: Renowned cardiovascular surgeon Dr.
- Naresh Trehan has issued a stern warning against the unsupervised use of GLP-1 (Glucagon-like peptide-1) drugs, which have flooded the Indian market following recent patent expirations.
- While originally developed in the U.S.